US 12,440,513 B2
Methods for improving cognitive function
Qi Yang, Glenmont, NY (US)
Assigned to Albany Medical College, Albany, NY (US)
Appl. No. 17/441,613
Filed by ALBANY MEDICAL COLLEGE, Albany, NY (US)
PCT Filed Mar. 20, 2020, PCT No. PCT/US2020/023800
§ 371(c)(1), (2) Date Sep. 21, 2021,
PCT Pub. No. WO2020/197984, PCT Pub. Date Oct. 1, 2020.
Claims priority of provisional application 62/822,159, filed on Mar. 22, 2019.
Prior Publication US 2022/0125849 A1, Apr. 28, 2022
Int. Cl. A61K 38/19 (2006.01); A61K 9/00 (2006.01); A61K 31/202 (2006.01); A61K 31/5575 (2006.01); A61K 35/17 (2015.01); A61K 35/26 (2015.01); A61K 35/741 (2015.01); A61K 38/20 (2006.01); A61K 39/395 (2006.01); A61P 25/28 (2006.01); C12N 5/078 (2010.01)
CPC A61K 35/26 (2013.01) [A61K 9/0024 (2013.01); A61K 31/202 (2013.01); A61K 31/5575 (2013.01); A61K 35/17 (2013.01); A61K 35/741 (2013.01); A61K 38/19 (2013.01); A61K 38/20 (2013.01); A61K 38/2033 (2013.01); A61K 38/2046 (2013.01); A61K 39/3955 (2013.01); A61P 25/28 (2018.01); C12N 5/0634 (2013.01)] 20 Claims
 
1. A method of treating, or preventing progression of, aging-associated cognitive decline in a subject, comprising
administering to the subject a cytokine selected from the group consisting of interleukin 5 (IL-5), interleukin 7 (IL-7), interleukin 25 (IL-25), thymic stromal lymphopoietin, and any combination of two or more of the foregoing, wherein the subject has aging-associated cognitive decline.